Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort.
Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, Scheenen T, Fütterer J, Bouwense S, van Oort I, Schröder F, Huisman H, Barentsz J. Hambrock T, et al. Among authors: van oort i. Eur Urol. 2012 Jan;61(1):177-84. doi: 10.1016/j.eururo.2011.08.042. Epub 2011 Aug 27. Eur Urol. 2012. PMID: 21924545
A comparison of machine learning models for predicting urinary incontinence in men with localized prostate cancer.
Hasannejadasl H, Osong B, Bermejo I, van der Poel H, Vanneste B, van Roermund J, Aben K, Zhang Z, Kiemeney L, Van Oort I, Verwey R, Hochstenbach L, Bloemen E, Dekker A, Fijten RRR. Hasannejadasl H, et al. Among authors: van roermund j, van oort i, van der poel h. Front Oncol. 2023 Apr 12;13:1168219. doi: 10.3389/fonc.2023.1168219. eCollection 2023. Front Oncol. 2023. PMID: 37124522 Free PMC article.
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators. Saad F, et al. Lancet Oncol. 2015 Mar;16(3):338-48. doi: 10.1016/S1470-2045(15)70027-6. Epub 2015 Feb 18. Lancet Oncol. 2015. PMID: 25701170 Clinical Trial.
DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.
Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. Hessels D, et al. Among authors: van balken b, van oort i, van leenders gj. Eur Urol. 2003 Jul;44(1):8-15; discussion 15-6. doi: 10.1016/s0302-2838(03)00201-x. Eur Urol. 2003. PMID: 12814669
Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility.
Hambrock T, Fütterer JJ, Huisman HJ, Hulsbergen-vandeKaa C, van Basten JP, van Oort I, Witjes JA, Barentsz JO. Hambrock T, et al. Among authors: van oort i, van basten jp. Invest Radiol. 2008 Oct;43(10):686-94. doi: 10.1097/RLI.0b013e31817d0506. Invest Radiol. 2008. PMID: 18791410
172 results